Guy S. Frcophth Negretti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guy S. Frcophth Negretti has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Mandeep S. Sagoo
Ocular Oncology Service, Moorfields Eye Hospital NHS Foundation Trust, London, UK
3 shared publications Alia Ahmad
University of Child Health Sciences and the Children's Hospital, Lahore, Pakistan
1 shared publication- Amit K. Arora
Ocular Oncology Service, Moorfields Eye Hospital, London EC1V 2PD, UK
1 shared publication - Bertil Damato
Ocular Oncology Service, Moorfields Eye Hospital, London, United Kingdom
1 shared publication Carol L. Shields
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania
1 shared publication- Caroline Thaung
University College London, Institute of Ophthalmology, London, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 1 September 2025
- Published by Wolters Kluwer Health in Retina
- Vol. 45 (9) , 1817-1821
DISSEMINATION OF UVEAL MELANOMA AFTER DIAGNOSTIC BIOPSY WITH 23-GAUGE VITRECTOR
Purpose: To report a case with tumor dissemination after diagnostic choroidal biopsy. Methods: Multimodal imaging and histopathology correlation. Results: A 64-year-old man presented with an atypical uveal mass and underwent a diagnostic transretinal 23-gauge vitrector biopsy to diagnose melanoma. Postoperative course was complicated by prolonged vitreous hemorrhage which required vitrectomy, delaying proton beam treatment by two months. One year after the biopsy, the tumor cells had disseminated to the retina, optic nerve, iris, iridocorneal angle, and extraocularly via the vitrectomy port. The patient died from metastatic melanoma 1 year later. To the best of our knowledge, there are 10 prior cases with biopsy-related tumor seeding in the literature, with risk features including multiple vitreous surgeries, a long interval between biopsy and treatment, and high-risk melanoma cytogenetics. Severe vitreous hemorrhage following biopsy further postpone treatments or warrant vitrectomy, both increasing the risk of tumor spread. Conclusion: Biopsy of choroidal melanoma, especially when complicated by severe vitreous hemorrhage, can lead to dissemination of the malignant tumor.
- 1 September 2025
- Published by Wolters Kluwer Health in Retina
- Vol. 45 (9) , 1817-1821
Open AccessDISSEMINATION OF UVEAL MELANOMA AFTER DIAGNOSTIC BIOPSY WITH 23-GAUGE VITRECTOR
Purpose: To report a case with tumor dissemination after diagnostic choroidal biopsy. Methods: Multimodal imaging and histopathology correlation. Results: A 64-year-old man presented with an atypical uveal mass and underwent a diagnostic transretinal 23-gauge vitrector biopsy to diagnose melanoma. Postoperative course was complicated by prolonged vitreous hemorrhage which required vitrectomy, delaying proton beam treatment by two months. One year after the biopsy, the tumor cells had disseminated to the retina, optic nerve, iris, iridocorneal angle, and extraocularly via the vitrectomy port. The patient died from metastatic melanoma 1 year later. To the best of our knowledge, there are 10 prior cases with biopsy-related tumor seeding in the literature, with risk features including multiple vitreous surgeries, a long interval between biopsy and treatment, and high-risk melanoma cytogenetics. Severe vitreous hemorrhage following biopsy further postpone treatments or warrant vitrectomy, both increasing the risk of tumor spread. Conclusion: Biopsy of choroidal melanoma, especially when complicated by severe vitreous hemorrhage, can lead to dissemination of the malignant tumor.
- 1 March 2025
- Published by Wolters Kluwer Health in Retina
- Vol. 45 (3) , 565-573
NEOVASCULAR GLAUCOMA AS A PREDICTOR OF RETINOBLASTOMA HIGH-RISK HISTOPATHOLOGY IN AN INTERNATIONAL MULTICENTER STUDY
Purpose: To assess histopathology and outcomes after primary enucleation of eyes with retinoblastoma presenting with neovascular glaucoma (NVG). Methods: This was an international multicenter case series study across five continents. A retrospective review of patient charts was performed for all patients undergoing primary enucleation for retinoblastoma (n = 1,420) using a standardized data-collection spreadsheet. Clinical features, pathologic grade, and outcomes were compared between NVG patients and those with an American Joint Commission on Cancer eighth edition clinical stage of cT2. High-risk histopathology was defined as American Joint Commission on Cancer eighth edition pathologic stage ≥ pT2b. Results: Neovascular glaucoma was seen in 224/1,420 (16%) patients. The mean age at presentation of those with NVG was 30 months (median 25, range 0–120 months), and 131 (58%) patients had high-risk histopathology. The univariate logistic regression odds ratio for NVG predicting high-risk histopathology was 1.73 (95% confidence interval: 1.3–2.31) and from multivariate logistic regression was 1.77 (95% confidence interval: 1.23–2.56). Patients with a longer duration of symptoms (P = 0.03), buphthalmos (P = 0.02), and ectropion uveae (P < 0.01) were more likely to have high-risk histopathology. Patients with NVG were more likely to develop metastasis than cT2 patients (P = 0.04). Conclusion: There is a significant association between NVG at presentation, high-risk histopathology, and metastatic risk.
- 1 March 2025
- Published by Wolters Kluwer Health in Retina
- Vol. 45 (3) , 565-573
NEOVASCULAR GLAUCOMA AS A PREDICTOR OF RETINOBLASTOMA HIGH-RISK HISTOPATHOLOGY IN AN INTERNATIONAL MULTICENTER STUDY
Purpose: To assess histopathology and outcomes after primary enucleation of eyes with retinoblastoma presenting with neovascular glaucoma (NVG). Methods: This was an international multicenter case series study across five continents. A retrospective review of patient charts was performed for all patients undergoing primary enucleation for retinoblastoma (n = 1,420) using a standardized data-collection spreadsheet. Clinical features, pathologic grade, and outcomes were compared between NVG patients and those with an American Joint Commission on Cancer eighth edition clinical stage of cT2. High-risk histopathology was defined as American Joint Commission on Cancer eighth edition pathologic stage ≥ pT2b. Results: Neovascular glaucoma was seen in 224/1,420 (16%) patients. The mean age at presentation of those with NVG was 30 months (median 25, range 0–120 months), and 131 (58%) patients had high-risk histopathology. The univariate logistic regression odds ratio for NVG predicting high-risk histopathology was 1.73 (95% confidence interval: 1.3–2.31) and from multivariate logistic regression was 1.77 (95% confidence interval: 1.23–2.56). Patients with a longer duration of symptoms (P = 0.03), buphthalmos (P = 0.02), and ectropion uveae (P < 0.01) were more likely to have high-risk histopathology. Patients with NVG were more likely to develop metastasis than cT2 patients (P = 0.04). Conclusion: There is a significant association between NVG at presentation, high-risk histopathology, and metastatic risk.
- Open Access
- 17 February 2025
- Published by Wolters Kluwer Health in Retina
- Vol. 45 (3) , 501-508
INTRAVITREAL BEVACIZUMAB FOR THE TREATMENT OF CHOROIDAL HEMANGIOMAS
Purpose: To investigate the use of intravitreal bevacizumab for the treatment of subretinal fluid (SRF) and intraretinal fluid associated with circumscribed choroidal hemangiomas. Methods: This was a retrospective review of all patients treated with at least three bevacizumab injections for circumscribed choroidal hemangiomas–associated SRF between May 2020 and August 2023 in Moorfields eye hospital. Outcome measures included change in best-corrected visual acuity, change in patient-reported symptoms, change in SRF, and change in central subfield thickness. Data on further management after cessation of injections were analyzed. Results: The study included nine patients. Median best-corrected visual acuity was 6/19 before and 6/24 after injections (P = 0.41). Central subfield thickness decreased from a median of 466 to 447 µm (P = 0.11). Two thirds of (n = 6) patients did not show any reduction in foveal SRF, one third (n = 3) showed a partial reduction, and no patients had a complete resolution of SRF. Eight patients received rescue-photodynamic therapy, and one received external beam radiotherapy. Best-corrected visual acuity changed from a median of 6/60 to a median of 6/12 after rescue treatment (P = 0.63). The median central subfield thickness decreased significantly from 470 µm to 249 µm (P = 0.01). Conclusion: Intravitreal bevacizumab is unlikely to be an effective treatment for exudative circumscribed choroidal hemangiomas.
- 17 February 2025
- Published by Wolters Kluwer Health in Retina
- Vol. 45 (3) , 501-508
Open AccessINTRAVITREAL BEVACIZUMAB FOR THE TREATMENT OF CHOROIDAL HEMANGIOMAS
Purpose: To investigate the use of intravitreal bevacizumab for the treatment of subretinal fluid (SRF) and intraretinal fluid associated with circumscribed choroidal hemangiomas. Methods: This was a retrospective review of all patients treated with at least three bevacizumab injections for circumscribed choroidal hemangiomas–associated SRF between May 2020 and August 2023 in Moorfields eye hospital. Outcome measures included change in best-corrected visual acuity, change in patient-reported symptoms, change in SRF, and change in central subfield thickness. Data on further management after cessation of injections were analyzed. Results: The study included nine patients. Median best-corrected visual acuity was 6/19 before and 6/24 after injections (P = 0.41). Central subfield thickness decreased from a median of 466 to 447 µm (P = 0.11). Two thirds of (n = 6) patients did not show any reduction in foveal SRF, one third (n = 3) showed a partial reduction, and no patients had a complete resolution of SRF. Eight patients received rescue-photodynamic therapy, and one received external beam radiotherapy. Best-corrected visual acuity changed from a median of 6/60 to a median of 6/12 after rescue treatment (P = 0.63). The median central subfield thickness decreased significantly from 470 µm to 249 µm (P = 0.01). Conclusion: Intravitreal bevacizumab is unlikely to be an effective treatment for exudative circumscribed choroidal hemangiomas.
- Open Access
Detecting Progression of Treated Choroidal Melanomas: Is Ultrasonography Necessary?
Prompt detection and treatment of local treatment failure after radiotherapy for choroidal melanoma optimises any opportunities for conserving vision and the eye, possibly reducing an increased risk of metastatic disease. Long-term surveillance is therefore required but is hampered by the perceived need to perform ultrasonography, which may not be available at a patient’s local hospital. The aim of this study was to determine whether local treatment failure can reliably be detected with colour fundus photography alone, and, if so, in which patients. Patients were included in the study if diagnosed with local treatment failure between April 2016 and February 2021 after eye-conserving therapy for choroidal melanoma. Wide-field colour and fundal autofluorescence (FAF) images, optical coherence tomography (OCT), and ultrasonography (US) were analysed by two of the authors (GN and UH). The cohort included 87 patients with local treatment failure. In 75 patients with clear media, tumour progression was detected by colour photography alone in 74 (98.7%) patients. Sensitivity was not increased by the addition of either OCT or AF. One patient with clear media developed extraocular extension detected with US without visible change in the intraocular part of the tumour. In the other 12 patients, US was required because of opaque media and a consequently poor fundal view. Local treatment failure after radiotherapy for choroidal melanoma is detected in 98.7% of cases with colour photography when the media are clear. Ultrasonography is useful when photography is prevented by opaque media or tumours having locations in the far periphery.
Open AccessDetecting Progression of Treated Choroidal Melanomas: Is Ultrasonography Necessary?
Prompt detection and treatment of local treatment failure after radiotherapy for choroidal melanoma optimises any opportunities for conserving vision and the eye, possibly reducing an increased risk of metastatic disease. Long-term surveillance is therefore required but is hampered by the perceived need to perform ultrasonography, which may not be available at a patient’s local hospital. The aim of this study was to determine whether local treatment failure can reliably be detected with colour fundus photography alone, and, if so, in which patients. Patients were included in the study if diagnosed with local treatment failure between April 2016 and February 2021 after eye-conserving therapy for choroidal melanoma. Wide-field colour and fundal autofluorescence (FAF) images, optical coherence tomography (OCT), and ultrasonography (US) were analysed by two of the authors (GN and UH). The cohort included 87 patients with local treatment failure. In 75 patients with clear media, tumour progression was detected by colour photography alone in 74 (98.7%) patients. Sensitivity was not increased by the addition of either OCT or AF. One patient with clear media developed extraocular extension detected with US without visible change in the intraocular part of the tumour. In the other 12 patients, US was required because of opaque media and a consequently poor fundal view. Local treatment failure after radiotherapy for choroidal melanoma is detected in 98.7% of cases with colour photography when the media are clear. Ultrasonography is useful when photography is prevented by opaque media or tumours having locations in the far periphery.